Human schistosomiasis in the post Mass Drug Administration (MDA) era by Mutapi, Francisca et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human Schistosomiasis in the post Mass Drug Administration
(MDA) era
Citation for published version:
Mutapi, F, Maizels, R, Fenwick, A & Woolhouse, M 2016, 'Human Schistosomiasis in the post Mass Drug
Administration (MDA) era' The Lancet Infectious Diseases. DOI: 10.1016/S1473-3099(16)30475-3
Digital Object Identifier (DOI):
10.1016/S1473-3099(16)30475-3
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
The Lancet Infectious Diseases
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
                             Elsevier Editorial System(tm) for The Lancet 
Infectious Diseases 
                                  Manuscript Draft 
 
 
Manuscript Number: THELANCETID-D-15-01417R1 
 
Title: Human Schistosomiasis in the post Mass Drug Administration (MDA) 
era  
 
Article Type: Unsolicited Review 
 
Corresponding Author: Dr. Mutapi Francisca, PhD 
 
Corresponding Author's Institution: University of Edinburgh 
 
First Author: Mutapi Francisca, PhD 
 
Order of Authors: Mutapi Francisca, PhD; Rick M Maizels, BSc, PhD; Alan 
Fenwick, BSc, PhD; Mark Woolhouse, BSc, PhD 
 
Abstract: Profound changes are occurring in the epidemiology of 
schistosomiasis, a neglected tropical disease caused by a chronic 
infection with parasitic helminths of the genus Schistosoma. 
Schistosomiasis affects 240 million people worldwide, mostly in sub-
Saharan Africa. The advent and proliferation of mass drug administration 
(MDA) programs using the drug praziquantel (PZQ) is resulting in 
substantial increases in the number of people, mainly school-aged 
children, being effectively treated, approaching the point where the 
majority of people in endemic areas will receive one or more treatments 
during their lifetimes. PZQ treatment not only cures infection but also 
frees the host from the powerful immunomodulatory action of the parasites 
and simultaneously enhances exposure to key parasite antigens, 
accelerating the development of protective acquired immunity, which takes 
many years to develop naturally. At a population level these changes 
constitute a substantial alteration to schistosome ecology in that the 
parasites are more likely to be exposed not only to PZQ directly but also 
to hosts with altered immune phenotypes. Here, we consider the 
consequences of this for schistosome biology and immuno-epidemiology and 
for public health. We anticipate that there could be significant impacts 
on chronic pathology, natural immunity, vaccine development strategies, 
immune disorders and drug efficacy. This makes for a complex picture that 
only will become apparent over timescales of decades. We recommend 
careful monitoring and evaluation to accompany the roll-out of MDA 
programs in order to ensure that the considerable health benefits to 
populations are achieved and sustained. 
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Summary: Profound changes are occurring in the epidemiology of schistosomiasis, 
a neglected tropical disease caused by a chronic infection with parasitic helminths of 
the genus Schistosoma. Schistosomiasis affects 240 million people worldwide, 
mostly in sub-Saharan Africa. The advent and proliferation of mass drug 
administration (MDA) programs using the drug praziquantel (PZQ) is resulting in 
substantial increases in the number of people, mainly school-aged children, being 
effectively treated, approaching the point where the majority of people in endemic 
areas will receive one or more treatments during their lifetimes. PZQ treatment not 
only cures infection but also frees the host from the powerful immunomodulatory 
action of the parasites and simultaneously enhances exposure to key parasite 
antigens, accelerating the development of protective acquired immunity, which takes 
many years to develop naturally. At a population level these changes constitute a 
substantial alteration to schistosome ecology in that the parasites are more likely to 
be exposed not only to PZQ directly but also to hosts with altered immune 
phenotypes. Here, we consider the consequences of this for schistosome biology 
and immuno-epidemiology and for public health. We anticipate that there could be 
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significant impacts on chronic pathology, natural immunity, vaccine development 
strategies, immune disorders and drug efficacy. This makes for a complex picture 
that only will become apparent over timescales of decades. We recommend careful 
monitoring and evaluation to accompany the roll-out of MDA programs in order to 
ensure that the considerable health benefits to populations are achieved and 
sustained. 
Introduction 
One of the greatest advances in improving human health in the tropics, particularly 
child health and development, has been the development of anthelminthic drugs and 
their subsequent distribution in mass drug administration (MDA) programs. MDA 
refers to the drug treatment of targeted populations regardless of individual infection 
status. MDA was first used in the 1930s in attempts to control malaria with the drug 
Plasmoquine, with mixed results1. MDA campaigns for schistosomiasis were carried 
out in Egypt in the 1950s using tartar emetic2, but because tarter emetic had limited 
efficacy and needed many daily injections, this was a false dawn for schistosome 
MDA. When praziquantel (PZQ) became available in the 1980s, MDA against 
schistosomiasis was slowly adopted as the major control strategy. Praziquantel is 
safe and efficacious, with cure rates as high as 100% as determined by 
parasitological methods of egg counts using urine filtration3 or Kato Katz 4. The drug 
is given as oral tablets at a dose of 40mg/kg body weight in Africa5  and 50mg/kg in 
adults and 60mg/kg in children in South America6. 
Current global initiatives following the guidelines for preventative chemotherapy set 
out by the World Health Organization (WHO), have implemented regular school-
based de-worming strategies in order to reduce development of severe morbidity, 
promote school-child health and improve the developmental potential of children. 
Many affected countries have now formulated helminth and trachoma control master 
plans targeting multiple diseases and specific vulnerable groups within the 
population. These programs are primarily focusing on onchocerciasis, lymphatic 
filariasis (LF), trachoma, schistosomiasis and soil transmitted helminths (STH) and 
are aimed at reducing infection and morbidity. LF and onchocerciasis programs are 
both aiming for elimination, but schistosomiasis and STH programs lag well behind. 
One exception is Zanzibar, where success in reducing the prevalence of 
schistosome infection has suggested the possibility of elimination7.  
In 2014, 56 million people in 27 countries (20 of them in Africa) received PZQ 
treatment for schistosomiasis and the aim is to increase this number steadily over 
the years 2016-20. In Sub-Saharan Africa alone, it is estimated that some 100 million 
school-aged children require treatment for schistosomiasis8, and Merck Soreno have 
pledged to donate 250 million tablets of PZQ annually to meet the need for 
treatment. With additional PZQ also available from World Vision, the World Bank and 
the UK Department for International Development, sufficient amounts should be 
available to deliver about 130 million treatments annually. Whether countries will 
have the funds and capacity to deliver these drugs to the rural populations will be the 
factor which determines whether schistosomiasis will be effectively controlled in the 
near future. Indeed, better implementation has been highlighted as a potential 
reason for the greater effectiveness of MDA programs in China compared to the 
Philippines9. However, it is clear that we are fast approaching the point where, for 
the first time in history, the majority of schistosome-infected people will receive 
treatment at some point during their lives (see Figure 1). In any event, it will be 
important to investigate the consequences of this massive MDA not only for 
measuring the success of the control programs and infection/transmission reduction, 
but also for understanding any changes in the epidemiology of schistosomiasis  
resulting from unprecedented levels of drug pressure. 
We have been involved in implementing as well as monitoring and evaluating 
schistosome control programs in several countries in Africa. Concurrently, we have 
been undertaking basic scientific research to inform the development and delivery of 
helminth interventions, including schistosomiasis control strategies. Our research 
has led us to contemplate what the human health and parasite population landscape 
will look like in both the short and longer terms following widespread MDA to control 
schistosome infection and morbidity. 
Malaria MDA programs offer valuable lessons on how to anticipate both failure and 
success in population-based parasite control programs (see review10). However, 
interpretation of the impact of malaria MDA programs is complicated by the fact that 
many malaria campaigns employed both MDA and integrated vector control 
approaches. For schistosomiasis, most people recognise that improvements in water 
supplies, sanitation and hygiene (WASH), will be needed if disease is to be 
eliminated and historically some countries, notably Egypt, have included WASH, as 
well as mollusciding to reduce numbers of intermediate host snails, though with 
mixed outcomes2. Current schistosomiasis control programs, however, 
predominantly rely on PZQ treatment which allows the effects of MDA to be 
assessed in the absence of the confounding effects of other interventions. To date, 
there here have been just two studies investigating the potential long term effects of 
MDA on the epidemiology of schistosomiasis, one study using infection data11, and 
the other using both infection data and immunology data12.  Here, we extend this 
work by discussing the potential effects of schistosomiasis MDA on other aspects of 
both the human and parasite populations.  
Studies in human populations have shown that protective immunity against 
schistosome infection does develop naturally, albeit over several years13. This slow 
development of protective acquired immunity has been partly attributed to the 
undoubted ability of the worms to modulate host immune responses14, thereby 
allowing the parasites to establish chronic infections. PZQ alters the schistosome 
calcium transport channels in the schistosome adult worm tegument increasing 
cellular ion permeability thus inducing spastic muscular paralysis15. This causes 
morphological changes in the schistosome tegument allowing greater exposure of 
parasite antigens and thereby driving stronger schistosome-specific antibody and 
cellular responses16. This damage to the tegument allows the host’s immune system 
to attack the worms leading to their death15. In addition, the clearance of the 
parasites also removes the cause of immunological down-modulation, so increasing 
the proportion and activation phenotype of antigen presenting cells, CD4+ effector 
and CD4+ memory T cells17, 18. These changes occur in both schistosome-specific 
and non-schistosome-specific cells and mechanistic studies in experimental models 
have shown that the relationship is causal (see review19) 
The consequences of these two PZQ-related effects on the intrinsic immune 
response of the infected host are that the antigen threshold required to mount 
protective immune responses is achieved20 and the cellular hypo-responsiveness 
induced by the parasites is reversed21. Furthermore, PZQ treatment can reverse 
early pathology in human infections22. This benefits the host in that both re-infection 
rates and subsequent immunopathology are reduced. Since resistance to 
schistosomiasis is only partial, people do still become re-infected but repeated 
treatment has been shown to have greater impact on reducing re-infection rates23. 
Although there is some heterogeneity in the effector responses induced by 
treatment24, data from field immuno-epidemiological studies suggest that the immune 
responses induced by treatment mirror protective immunity that develops naturally, 
indicating that PZQ treatment accelerates a process that takes years to occur in 
untreated individuals25.  
The frequency of PZQ MDA has been prescribed for primary school children by the 
WHO and ranges from once every 1-2 years to once over the 7 primary school years 
for each child depending on levels of transmission26. In countries such as Zimbabwe, 
ministries of health have embarked on an annual treatment for every schistosome-
exposed school child regardless of the level of transmission, so every child will 
receive up to 5 treatments, but children who miss one year may well be treated in the 
following year, thus ensuring good coverage. However, as has occurred in other 
countries, MDA programs run for a specified pre-defined period, for example 
Zimbabwe’s MDA programme is running for 5 years from 2012 to 2016. Other MDA 
programs may not be continued, for various reasons including financial and political 
willpower9, 27. In either case, residual foci of transmission may lead to people in 
affected areas carrying infections without the benefit of treatment28. Importantly, it is 
still not known how long immune responses will persist or decay once the source of 
antigenic stimulation is removed.   
Our prediction is that, in addition to substantially reducing levels of infection, the 
MDA programs will initially boost schistosome-specific protective responses in the 
school-aged population and this will contribute to a reduction in re-infection rates12. 
This prediction is supported by work on Kenyan car washers23 and Zimbabwean 
children29 who showed significant reductions in re-infection rates (accompanied by 
significant changes in their immune phenotype) during the 91 and 75 weeks 
following treatment respectively  
However, it remains unclear for how long this level of acquired resistance will be 
maintained in the face of reduced natural exposure to infection to boost protective 
immunity as well as in the absence of large amounts of antigen released through the 
killing of worms by PZQ16. The long-term effects of PZQ treatment on host immune 
phenotype remain unexplored as there have not been any studies investigating the 
effects of these changes several years after cessation of MDA. Nonetheless, in the 
case of schistosome-specific responses and susceptibility to re-infection, we have 
demonstrated that cessation of MDA after 5 years in areas where there has not been 
a sustained reduction in overall transmission rate (as might occur in the absence of 
additional complementary interventions) can impact on the development of 
schistosome-specific responses12. There has already been a precedent in malaria, 
where following cessation of MDA in Tanzanian children, among whom those who 
had received malaria chemoprophylaxis had higher rates of pathology (severe 
malaria) and anaemia compared to non-chemoprophylaxis groups, a difference 
attributed to the lack of development of naturally acquired protection in the treated 
group30. Decay in protective immunity could lead to a rebound in schistosome 
infection to levels higher than those before treatment once drug protection ceases 
(see Figure 3). Indeed a rebound in schistosome infection and morbidity after MDA 
cessation has already been reported from Pemba and Mali 27,31, and this is 
consistent with predictions from quantitative analyses12. 
There is also a need to predict the effect of superimposing an anti-schistosome 
vaccine, when one becomes available, on populations already naturally exposed to 
the parasite and treated with PZQ, and thus having some partial protection against 
infection/re-infection. Interestingly, we have shown16 that PZQ treatment enhances 
immune responses against every WHO schistosome vaccine candidate antigen, 
including the 28-kDa glutathione S transferase (28kDa GST) formulated as Bilhvax© 
(see Figure 2) which has undergone Phase III clinical trials.  Consequently, we have 
highlighted that the choice of study design and controls in the post-MDA 
schistosome vaccine trials would need very careful consideration in order to detect 
the effects of vaccination above and beyond those of treatment32.  
In experimental models, regulatory responses induced as part of the 
immunomodulatory mechanisms employed by helminths to evade host immune 
attack, reduce the severity or incidence of immune disorders such as colitis and 
allergic airway inflammation (see review19). Several human studies including our 
own, have shown that PZQ treatment increases immune reactivity against allergens 
and self- or autoantigens. In theory, this gives rise to the potential for PZQ MDA to 
exacerbate the clinical manifestations of these  immune disorders19, generating 
concerns that MDA programs could lead to increased levels of these immune 
disorders in treated populations.  However, in practice, these concerns have not 
been realised. Broadly, the immunological changes in allergic and/or autoimmune 
reactivity are quantitative uplifts that do not translate to clinical disease. Indeed there 
are several studies documenting that sensitization to one or more allergens may be 
highly prevalent without manifesting as a clinically relevant allergy33,34. Similarly, 
autoreactivity alone does not indicate clinical autoimmune disease. This suggests 
the existence of complex features of the immune system preventing the translation of 
immunological changes to clinical pathology in helminth-infected individuals, some of 
which we have studied in affected human populations: for example, the uncoupling 
of allergic reactivity and clinical disease through higher ratios of  total to allergen-
specific serum IgE and the epitope specificity of the IgE35.  It is also worth factoring 
in other homeostatic features of the immune system that influence the impact of 
helminth infections on host health such as the gut microbiome36. For example, we 
have recently demonstrated that in children aged 6 months to 10 years, the gut 
microbiome abundance and diversity are refractory to PZQ treatment of S. 
haematobium infection37. Hence, there is a need to continue monitoring the long-
term effects of PZQ treatment on these responses and clinical disease status in the 
relevant MDA target populations with the understanding that immunological changes 
may take months or years to manifest themselves given the complex dynamics of 
each component in the immune response. 
Also worthy of consideration is the converse side of these immunological changes; 
i.e. the different type of environment for schistosomes that a treated host constitutes 
and the potential for this new environment to drive selection for different schistosome 
genotypes/phenotypes. Experimental studies show that schistosome worms show 
plasticity in their development depending on the host immune phenotype; for 
example, the development of male worms is dependent on signals from the host 
immune system38. The effects of MDA on the developmental plasticity of 
schistosomes remain to be investigated, particularly to determine if schistosome 
transmission and life cycle propagation are altered under MDA pressure as a result 
of changes in the host immunological environment. Although parasite transmission 
should be reduced, in theory, there may be an overall increase in fecundity or 
virulence; an experimental study with Plasmodium chabaudi  found that parasites 
developing in the face of immunity were more pathogenic when transferred to naïve 
hosts39.  
In a recent meta-analysis of 55 reports of trials of PZQ efficacy, egg reduction rates 
ranged from 72% to 100% and cure rates ranged from 48% to 100%40. Although this 
heterogeneity arises from several factors, not least pre-treatment infection levels, the 
effects of differences in host factors cannot be excluded and there is a need to 
determine whether certain human phenotypes or genotypes will harbour a reservoir 
of schistosome parasites despite PZQ treatment. Such human refugia might need 
supplementary targeting, and immunological and/or biochemical profiling could help 
predict individuals in whom treatment failures will occur and these can be targeted by 
selective population chemotherapy. This may require infection diagnostics more 
sensitive than parasitological methods, such as antigen-based diagnostics, to ensure 
identification of people harbouring a reservoir of parasites41.  
 
An important host variable is likely to be in pharmacokinetics, which may affect the 
amount of therapeutic PZQ in the host. One explanation proposed for lower re-
infection rates in children treated with 60mg compared to 40mg/kg body weight was 
potential differences in immune responses resulting from treatment with different 
PZQ doses5.  PZQ is metabolised by the cytochrome P450 (CYP) enzyme system in 
the liver42. Differential expression of these enzymes makes its availability susceptible 
to variability arising from individual pharmacokinetic heterogeneity, interactions with 
drugs/substances that induce/inhibit specific isoenzymes of the CYP system taken 
concomitantly with PZQ, and liver function (e.g. rifampicin used to treat 
Mycobacterium tuberculosis infection can reduce the amount of PZQ released in the 
host to below therapeutic levels43). To date, no extensive studies have been 
conducted to ascertain the relative contribution of these variables in the metabolism 
and efficacy of PZQ, and the resultant break-through of parasites despite treatment. 
Similarly, the level of polymorphism in the isoenzymes of the CYP system44 has not 
been documented in the MDA target populations, nor has there been quantification 
of the scale of people taking PZQ concurrently with drugs that affect the 
bioavailability of PZQ.  
 
One of the main concerns for any parasite control program heavily reliant on drug 
intervention is possible selection for drug-resistant parasites. The effects of PZQ 
MDA on schistosome genetic diversity remain inconclusive45. So far, there have 
been no validated reports of drug resistance to PZQ amongst schistosome worms in 
human populations, and both field and quantitative studies refute the rapid 
development of PZQ resistance46. Nonetheless, heritable variation in PZQ sensitivity 
has been shown in schistosome worms experimentally, thus indicating that 
schistosome worms have the capacity to develop some level of resistance to PZQ47, 
48, 49. Phylogenetic analyses and indices of schistosome parasite population 
differentiation have been able to distinguish parasites acquired through re-infection 
from those which have survived following PZQ treatment50. This, combined with host 
genotype characterisation will be useful for indicating putatively resistant parasites 
and hosts non-responsive to PZQ treatment. The advent of schistosome resistance 
to Oxamniquine in the 1970s that halted the S. mansoni MDA program in Brazil 
using this drug51 indicates a need for complementary interventions for long-term 
schistosome control programs. 
Consequences of MDA on schistosome population biology include the potential for 
hybridisation between anthroponotic and zoonotic schistosomes, for example S. 
haematobium worms can hybridise with S. intercalatum  or S. mansoni52 as well as 
with S. curassoni and S. bovis53. The ability of the ‘human’ schistosomes to hybridise 
with the animal schistosomes not only provides the potential for extending the host 
range, but may also affect pathogenicity52. Field studies have already shown that in 
areas co-endemic for S. mansoni and S. haematobium, the efficacy of PZQ can 
differ between the species54, and that competition for mates and ‘over-spill’ can 
result in hybridisation55.  Taking the different efficacy of PZQ in the two main human 
schistosome species that are co-endemic in some African regions (S. mansoni and 
S. haematobium), hybridisation and its effects on pathology/morbidity require 
monitoring and further investigation.  
In order to track the effects of MDA on overall host health and parasite population 
biology and, more crucially, to make predictions that can inform public health 
interventions and policy, it is essential that host and parasite schistosome 
epidemiology are closely monitored and related to molecular and genetic 
characteristics of each. This means following the effects of PZQ MDA on the 
classical schistosome epidemiological patterns13 and determining whether MDA 
programs (1) increase (or decrease) heterogeneity of host immune responses, (2) 
increase or decrease aggregation of infection, and (3) alter the age distribution of 
infection. It is also important to determine the effects of MDA frequency on these 
patterns in the populations exposed to different schistosome transmission levels56.  
With the ultimate goal being improvement of both the short- and long-term health 
status of at-risk populations, the effects and strategies of schistosome interventions 
must continually be monitored and evaluated in the light of accumulating scientific 
evidence. Schistosomes have been shown to survive for many years in the host and 
host responses to schistosome infection develop over similar time scales. As a 
consequence, population-level shifts in schistosome immune-epidemiology take 
place slowly, over time-scales of decades13. Changes in schistosome genetics may 
occur over even longer time scales. Current evidence indicates that there are 
significant health benefits to receiving PZQ MDA, with very little downside to MDA, 
but it is important that we learn how to sustain these benefits for future generations. 
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Figure 1: Heat map showing the estimated number of school age children requiring 
annual treatment for schistosomiasis (preventative chemotherapy) in countries 
where the disease is endemic.  Black dots indicate countries where there has been a 
MDA program using Praziquantel within the past 5 years (2010-2015). Data obtained 
from the World Health Organisation Preventative Chemotherapy databank 
(http://www.who.int/neglected_diseases/preventive_chemotherapy/sch/en/). 
 
Figure 2: Effects of PZQ on human schistosome specific antibody responses 
(adopted from ref 16)  
2-dimensional Western blot analyses of serological reactivity of the treated cohort 
comparing pre- and post-treatment responses. The intensity of the IgG1 reactivity 
against adult schistosome worm antigens in serum pooled from 112 people (male 
and female) aged 5-42 was compare before and 12 weeks after treatment with the 
standard dose of Praziquantel (PZQ) of 40mg/kg body weight. (Full details are given 
in ref16) 
a) Spots (antigens) reacting with sera collected at time 0 (before PZQ 
treatment). Boxes represent the position where additional spots absent in this Figure 
are present in Figure 2b.  
b) Spots reacting with sera collected 12 weeks post-treatment. In addition to 
enhanced recognition of antigens recognised before treatment, additional antigens 
highlighted in the numbered boxes were identified.  
c) Protein identities of the antigens identified by sera after treatment.  The 
proteins highlighted in bold are on the current  World Health Organisation list of 
schistosome vaccine candidates (see http://www.who.int/immunization/diseases/en/) 
 
Figure 3: Model-predicted dynamics of protective antibody and egg output during 
and after MDA for schistosomiasis. Treatment applied at yearly intervals for 5 years 
(asterisks) to a large population of school-aged children (6-15 years old) with 75% 
coverage. (a) Antibody levels.  (b) Egg output. Figures compare results when MDA 
reduces transmission by 0, 50 or 100%. This model assumes a relatively short-lived 
memory response and a worm life span of 6.5 years. Full details are given in ref 12.  
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Summary: Profound changes are occurring in the epidemiology of schistosomiasis, 
a neglected tropical disease caused by a chronic infection with parasitic helminths of 
the genus Schistosoma. Schistosomiasis affects 240 million people worldwide, 
mostly in sub-Saharan Africa. The advent and proliferation of mass drug 
administration (MDA) programs using the drug praziquantel (PZQ) is resulting in 
substantial increases in the number of people, mainly school-aged children, being 
effectively treated, approaching the point where the majority of people in endemic 
areas will receive one or more treatments during their lifetimes. PZQ treatment not 
only cures infection but also frees the host from the powerful immunomodulatory 
action of the parasites and simultaneously enhances exposure to key parasite 
antigens, accelerating the development of protective acquired immunity, which takes 
many years to develop naturally. At a population level these changes constitute a 
substantial alteration to schistosome ecology in that the parasites are more likely to 
be exposed not only to PZQ directly but also to hosts with altered immune 
phenotypes. Here, we consider the consequences of this for schistosome biology 
and immuno-epidemiology and for public health. We anticipate that there could be 
*Manuscript
significant impacts on chronic pathology, natural immunity, vaccine development 
strategies, immune disorders and drug efficacy. This makes for a complex picture 
that only will become apparent over timescales of decades. We recommend careful 
monitoring and evaluation to accompany the roll-out of MDA programs in order to 
ensure that the considerable health benefits to populations are achieved and 
sustained. 
Introduction 
One of the greatest advances in improving human health in the tropics, particularly 
child health and development, has been the development of anthelminthic drugs and 
their subsequent distribution in mass drug administration (MDA) programs. MDA 
refers to the drug treatment of targeted populations regardless of individual infection 
status. MDA was first used in the 1930s in attempts to control malaria with the drug 
Plasmoquine, with mixed results1. MDA campaigns for schistosomiasis were carried 
out in Egypt in the 1950s using tartar emetic2, but because tarter emetic had limited 
efficacy and needed many daily injections, this was a false dawn for schistosome 
MDA. When praziquantel (PZQ) became available in the 1980s, MDA against 
schistosomiasis was slowly adopted as the major control strategy. Praziquantel is 
safe and efficacious, with cure rates as high as 100% as determined by 
parasitological methods of egg counts using urine filtration3 or Kato Katz 4. The drug 
is given as oral tablets at a dose of 40mg/kg body weight in Africa5  and 50mg/kg in 
adults and 60mg/kg in children in South America6. 
Current global initiatives following the guidelines for preventative chemotherapy set 
out by the World Health Organization (WHO), have implemented regular school-
based de-worming strategies in order to reduce development of severe morbidity, 
promote school-child health and improve the developmental potential of children. 
Many affected countries have now formulated helminth and trachoma control master 
plans targeting multiple diseases and specific vulnerable groups within the 
population. These programs are primarily focusing on onchocerciasis, lymphatic 
filariasis (LF), trachoma, schistosomiasis and soil transmitted helminths (STH) and 
are aimed at reducing infection and morbidity. LF and onchocerciasis programs are 
both aiming for elimination, but schistosomiasis and STH programs lag well behind. 
One exception is Zanzibar, where success in reducing the prevalence of 
schistosome infection has suggested the possibility of elimination7.  
In 2014, 56 million people in 27 countries (20 of them in Africa) received PZQ 
treatment for schistosomiasis and the aim is to increase this number steadily over 
the years 2016-20. In Sub-Saharan Africa alone, it is estimated that some 100 million 
school-aged children require treatment for schistosomiasis8, and Merck Soreno have 
pledged to donate 250 million tablets of PZQ annually to meet the need for 
treatment. With additional PZQ also available from World Vision, the World Bank and 
the UK Department for International Development, sufficient amounts should be 
available to deliver about 130 million treatments annually. Whether countries will 
have the funds and capacity to deliver these drugs to the rural populations will be the 
factor which determines whether schistosomiasis will be effectively controlled in the 
near future. Indeed, better implementation has been highlighted as a potential 
reason for the greater effectiveness of MDA programs in China compared to the 
Philippines9. However, it is clear that we are fast approaching the point where, for 
the first time in history, the majority of schistosome-infected people will receive 
treatment at some point during their lives (see Figure 1). In any event, it will be 
important to investigate the consequences of this massive MDA not only for 
measuring the success of the control programs and infection/transmission reduction, 
but also for understanding any changes in the epidemiology of schistosomiasis  
resulting from unprecedented levels of drug pressure. 
We have been involved in implementing as well as monitoring and evaluating 
schistosome control programs in several countries in Africa. Concurrently, we have 
been undertaking basic scientific research to inform the development and delivery of 
helminth interventions, including schistosomiasis control strategies. Our research 
has led us to contemplate what the human health and parasite population landscape 
will look like in both the short and longer terms following widespread MDA to control 
schistosome infection and morbidity. 
Malaria MDA programs offer valuable lessons on how to anticipate both failure and 
success in population-based parasite control programs (see review10). However, 
interpretation of the impact of malaria MDA programs is complicated by the fact that 
many malaria campaigns employed both MDA and integrated vector control 
approaches. For schistosomiasis, most people recognise that improvements in water 
supplies, sanitation and hygiene (WASH), will be needed if disease is to be 
eliminated and historically some countries, notably Egypt, have included WASH, as 
well as mollusciding to reduce numbers of intermediate host snails, though with 
mixed outcomes2. Current schistosomiasis control programs, however, 
predominantly rely on PZQ treatment which allows the effects of MDA to be 
assessed in the absence of the confounding effects of other interventions. To date, 
there here have been just two studies investigating the potential long term effects of 
MDA on the epidemiology of schistosomiasis, one study using infection data11, and 
the other using both infection data and immunology data12.  Here, we extend this 
work by discussing the potential effects of schistosomiasis MDA on other aspects of 
both the human and parasite populations.  
Studies in human populations have shown that protective immunity against 
schistosome infection does develop naturally, albeit over several years13. This slow 
development of protective acquired immunity has been partly attributed to the 
undoubted ability of the worms to modulate host immune responses14, thereby 
allowing the parasites to establish chronic infections. PZQ alters the schistosome 
calcium transport channels in the schistosome adult worm tegument increasing 
cellular ion permeability thus inducing spastic muscular paralysis15. This causes 
morphological changes in the schistosome tegument allowing greater exposure of 
parasite antigens and thereby driving stronger schistosome-specific antibody and 
cellular responses16. This damage to the tegument allows the host’s immune system 
to attack the worms leading to their death15. In addition, the clearance of the 
parasites also removes the cause of immunological down-modulation, so increasing 
the proportion and activation phenotype of antigen presenting cells, CD4+ effector 
and CD4+ memory T cells17, 18. These changes occur in both schistosome-specific 
and non-schistosome-specific cells and mechanistic studies in experimental models 
have shown that the relationship is causal (see review19) 
The consequences of these two PZQ-related effects on the intrinsic immune 
response of the infected host are that the antigen threshold required to mount 
protective immune responses is achieved20 and the cellular hypo-responsiveness 
induced by the parasites is reversed21. Furthermore, PZQ treatment can reverse 
early pathology in human infections22. This benefits the host in that both re-infection 
rates and subsequent immunopathology are reduced. Since resistance to 
schistosomiasis is only partial, people do still become re-infected but repeated 
treatment has been shown to have greater impact on reducing re-infection rates23. 
Although there is some heterogeneity in the effector responses induced by 
treatment24, data from field immuno-epidemiological studies suggest that the immune 
responses induced by treatment mirror protective immunity that develops naturally, 
indicating that PZQ treatment accelerates a process that takes years to occur in 
untreated individuals25.  
The frequency of PZQ MDA has been prescribed for primary school children by the 
WHO and ranges from once every 1-2 years to once over the 7 primary school years 
for each child depending on levels of transmission26. In countries such as Zimbabwe, 
ministries of health have embarked on an annual treatment for every schistosome-
exposed school child regardless of the level of transmission, so every child will 
receive up to 5 treatments, but children who miss one year may well be treated in the 
following year, thus ensuring good coverage. However, as has occurred in other 
countries, MDA programs run for a specified pre-defined period, for example 
Zimbabwe’s MDA programme is running for 5 years from 2012 to 2016. Other MDA 
programs may not be continued, for various reasons including financial and political 
willpower9, 27. In either case, residual foci of transmission may lead to people in 
affected areas carrying infections without the benefit of treatment28. Importantly, it is 
still not known how long immune responses will persist or decay once the source of 
antigenic stimulation is removed.   
Our prediction is that, in addition to substantially reducing levels of infection, the 
MDA programs will initially boost schistosome-specific protective responses in the 
school-aged population and this will contribute to a reduction in re-infection rates12. 
This prediction is supported by work on Kenyan car washers23 and Zimbabwean 
children29 who showed significant reductions in re-infection rates (accompanied by 
significant changes in their immune phenotype) during the 91 and 75 weeks 
following treatment respectively  
However, it remains unclear for how long this level of acquired resistance will be 
maintained in the face of reduced natural exposure to infection to boost protective 
immunity as well as in the absence of large amounts of antigen released through the 
killing of worms by PZQ16. The long-term effects of PZQ treatment on host immune 
phenotype remain unexplored as there have not been any studies investigating the 
effects of these changes several years after cessation of MDA. Nonetheless, in the 
case of schistosome-specific responses and susceptibility to re-infection, we have 
demonstrated that cessation of MDA after 5 years in areas where there has not been 
a sustained reduction in overall transmission rate (as might occur in the absence of 
additional complementary interventions) can impact on the development of 
schistosome-specific responses12. There has already been a precedent in malaria, 
where following cessation of MDA in Tanzanian children, among whom those who 
had received malaria chemoprophylaxis had higher rates of pathology (severe 
malaria) and anaemia compared to non-chemoprophylaxis groups, a difference 
attributed to the lack of development of naturally acquired protection in the treated 
group30. Decay in protective immunity could lead to a rebound in schistosome 
infection to levels higher than those before treatment once drug protection ceases 
(see Figure 3). Indeed a rebound in schistosome infection and morbidity after MDA 
cessation has already been reported from Pemba and Mali 27,31, and this is 
consistent with predictions from quantitative analyses12. 
There is also a need to predict the effect of superimposing an anti-schistosome 
vaccine, when one becomes available, on populations already naturally exposed to 
the parasite and treated with PZQ, and thus having some partial protection against 
infection/re-infection. Interestingly, we have shown16 that PZQ treatment enhances 
immune responses against every WHO schistosome vaccine candidate antigen, 
including the 28-kDa glutathione S transferase (28kDa GST) formulated as Bilhvax© 
(see Figure 2) which has undergone Phase III clinical trials.  Consequently, we have 
highlighted that the choice of study design and controls in the post-MDA 
schistosome vaccine trials would need very careful consideration in order to detect 
the effects of vaccination above and beyond those of treatment32.  
In experimental models, regulatory responses induced as part of the 
immunomodulatory mechanisms employed by helminths to evade host immune 
attack, reduce the severity or incidence of immune disorders such as colitis and 
allergic airway inflammation (see review19). Several human studies including our 
own, have shown that PZQ treatment increases immune reactivity against allergens 
and self- or autoantigens. In theory, this gives rise to the potential for PZQ MDA to 
exacerbate the clinical manifestations of these  immune disorders19, generating 
concerns that MDA programs could lead to increased levels of these immune 
disorders in treated populations.  However, in practice, these concerns have not 
been realised. Broadly, the immunological changes in allergic and/or autoimmune 
reactivity are quantitative uplifts that do not translate to clinical disease. Indeed there 
are several studies documenting that sensitization to one or more allergens may be 
highly prevalent without manifesting as a clinically relevant allergy33,34. Similarly, 
autoreactivity alone does not indicate clinical autoimmune disease. This suggests 
the existence of complex features of the immune system preventing the translation of 
immunological changes to clinical pathology in helminth-infected individuals, some of 
which we have studied in affected human populations: for example, the uncoupling 
of allergic reactivity and clinical disease through higher ratios of  total to allergen-
specific serum IgE and the epitope specificity of the IgE35.  It is also worth factoring 
in other homeostatic features of the immune system that influence the impact of 
helminth infections on host health such as the gut microbiome36. For example, we 
have recently demonstrated that in children aged 6 months to 10 years, the gut 
microbiome abundance and diversity are refractory to PZQ treatment of S. 
haematobium infection37. Hence, there is a need to continue monitoring the long-
term effects of PZQ treatment on these responses and clinical disease status in the 
relevant MDA target populations with the understanding that immunological changes 
may take months or years to manifest themselves given the complex dynamics of 
each component in the immune response. 
Also worthy of consideration is the converse side of these immunological changes; 
i.e. the different type of environment for schistosomes that a treated host constitutes 
and the potential for this new environment to drive selection for different schistosome 
genotypes/phenotypes. Experimental studies show that schistosome worms show 
plasticity in their development depending on the host immune phenotype; for 
example, the development of male worms is dependent on signals from the host 
immune system38. The effects of MDA on the developmental plasticity of 
schistosomes remain to be investigated, particularly to determine if schistosome 
transmission and life cycle propagation are altered under MDA pressure as a result 
of changes in the host immunological environment. Although parasite transmission 
should be reduced, in theory, there may be an overall increase in fecundity or 
virulence; an experimental study with Plasmodium chabaudi  found that parasites 
developing in the face of immunity were more pathogenic when transferred to naïve 
hosts39.  
In a recent meta-analysis of 55 reports of trials of PZQ efficacy, egg reduction rates 
ranged from 72% to 100% and cure rates ranged from 48% to 100%40. Although this 
heterogeneity arises from several factors, not least pre-treatment infection levels, the 
effects of differences in host factors cannot be excluded and there is a need to 
determine whether certain human phenotypes or genotypes will harbour a reservoir 
of schistosome parasites despite PZQ treatment. Such human refugia might need 
supplementary targeting, and immunological and/or biochemical profiling could help 
predict individuals in whom treatment failures will occur and these can be targeted by 
selective population chemotherapy. This may require infection diagnostics more 
sensitive than parasitological methods, such as antigen-based diagnostics, to ensure 
identification of people harbouring a reservoir of parasites41.  
 
An important host variable is likely to be in pharmacokinetics, which may affect the 
amount of therapeutic PZQ in the host. One explanation proposed for lower re-
infection rates in children treated with 60mg compared to 40mg/kg body weight was 
potential differences in immune responses resulting from treatment with different 
PZQ doses5.  PZQ is metabolised by the cytochrome P450 (CYP) enzyme system in 
the liver42. Differential expression of these enzymes makes its availability susceptible 
to variability arising from individual pharmacokinetic heterogeneity, interactions with 
drugs/substances that induce/inhibit specific isoenzymes of the CYP system taken 
concomitantly with PZQ, and liver function (e.g. rifampicin used to treat 
Mycobacterium tuberculosis infection can reduce the amount of PZQ released in the 
host to below therapeutic levels43). To date, no extensive studies have been 
conducted to ascertain the relative contribution of these variables in the metabolism 
and efficacy of PZQ, and the resultant break-through of parasites despite treatment. 
Similarly, the level of polymorphism in the isoenzymes of the CYP system44 has not 
been documented in the MDA target populations, nor has there been quantification 
of the scale of people taking PZQ concurrently with drugs that affect the 
bioavailability of PZQ.  
 
One of the main concerns for any parasite control program heavily reliant on drug 
intervention is possible selection for drug-resistant parasites. The effects of PZQ 
MDA on schistosome genetic diversity remain inconclusive45. So far, there have 
been no validated reports of drug resistance to PZQ amongst schistosome worms in 
human populations, and both field and quantitative studies refute the rapid 
development of PZQ resistance46. Nonetheless, heritable variation in PZQ sensitivity 
has been shown in schistosome worms experimentally, thus indicating that 
schistosome worms have the capacity to develop some level of resistance to PZQ47, 
48, 49. Phylogenetic analyses and indices of schistosome parasite population 
differentiation have been able to distinguish parasites acquired through re-infection 
from those which have survived following PZQ treatment50. This, combined with host 
genotype characterisation will be useful for indicating putatively resistant parasites 
and hosts non-responsive to PZQ treatment. The advent of schistosome resistance 
to Oxamniquine in the 1970s that halted the S. mansoni MDA program in Brazil 
using this drug51 indicates a need for complementary interventions for long-term 
schistosome control programs. 
Consequences of MDA on schistosome population biology include the potential for 
hybridisation between anthroponotic and zoonotic schistosomes, for example S. 
haematobium worms can hybridise with S. intercalatum  or S. mansoni52 as well as 
with S. curassoni and S. bovis53. The ability of the ‘human’ schistosomes to hybridise 
with the animal schistosomes not only provides the potential for extending the host 
range, but may also affect pathogenicity52. Field studies have already shown that in 
areas co-endemic for S. mansoni and S. haematobium, the efficacy of PZQ can 
differ between the species54, and that competition for mates and ‘over-spill’ can 
result in hybridisation55.  Taking the different efficacy of PZQ in the two main human 
schistosome species that are co-endemic in some African regions (S. mansoni and 
S. haematobium), hybridisation and its effects on pathology/morbidity require 
monitoring and further investigation.  
In order to track the effects of MDA on overall host health and parasite population 
biology and, more crucially, to make predictions that can inform public health 
interventions and policy, it is essential that host and parasite schistosome 
epidemiology are closely monitored and related to molecular and genetic 
characteristics of each. This means following the effects of PZQ MDA on the 
classical schistosome epidemiological patterns13 and determining whether MDA 
programs (1) increase (or decrease) heterogeneity of host immune responses, (2) 
increase or decrease aggregation of infection, and (3) alter the age distribution of 
infection. It is also important to determine the effects of MDA frequency on these 
patterns in the populations exposed to different schistosome transmission levels56.  
With the ultimate goal being improvement of both the short- and long-term health 
status of at-risk populations, the effects and strategies of schistosome interventions 
must continually be monitored and evaluated in the light of accumulating scientific 
evidence. Schistosomes have been shown to survive for many years in the host and 
host responses to schistosome infection develop over similar time scales. As a 
consequence, population-level shifts in schistosome immune-epidemiology take 
place slowly, over time-scales of decades13. Changes in schistosome genetics may 
occur over even longer time scales. Current evidence indicates that there are 
significant health benefits to receiving PZQ MDA, with very little downside to MDA, 
but it is important that we learn how to sustain these benefits for future generations. 
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Figure 1: Heat map showing the estimated number of school age children requiring 
annual treatment for schistosomiasis (preventative chemotherapy) in countries 
where the disease is endemic.  Black dots indicate countries where there has been a 
MDA program using Praziquantel within the past 5 years (2010-2015). Data obtained 
from the World Health Organisation Preventative Chemotherapy databank 
(http://www.who.int/neglected_diseases/preventive_chemotherapy/sch/en/). 
 
Figure 2: Effects of PZQ on human schistosome specific antibody responses 
(adopted from ref 16)  
2-dimensional Western blot analyses of serological reactivity of the treated cohort 
comparing pre- and post-treatment responses. The intensity of the IgG1 reactivity 
against adult schistosome worm antigens in serum pooled from 112 people (male 
and female) aged 5-42 was compare before and 12 weeks after treatment with the 
standard dose of Praziquantel (PZQ) of 40mg/kg body weight. (Full details are given 
in ref16) 
a) Spots (antigens) reacting with sera collected at time 0 (before PZQ 
treatment). Boxes represent the position where additional spots absent in this Figure 
are present in Figure 2b.  
b) Spots reacting with sera collected 12 weeks post-treatment. In addition to 
enhanced recognition of antigens recognised before treatment, additional antigens 
highlighted in the numbered boxes were identified.  
c) Protein identities of the antigens identified by sera after treatment.  The 
proteins highlighted in bold are on the current  World Health Organisation list of 
schistosome vaccine candidates (see http://www.who.int/immunization/diseases/en/) 
 
Figure 3: Model-predicted dynamics of protective antibody and egg output during 
and after MDA for schistosomiasis. Treatment applied at yearly intervals for 5 years 
(asterisks) to a large population of school-aged children (6-15 years old) with 75% 
coverage. (a) Antibody levels.  (b) Egg output. Figures compare results when MDA 
reduces transmission by 0, 50 or 100%. This model assumes a relatively short-lived 
memory response and a worm life span of 6.5 years. Full details are given in ref 12.  
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c) Spot number Protein Identity (from Mass Spectrometry)
1 Triosephosphate isomerase
2 28kDa glutathione-S-transferase
3 Tropomyosin 1
4 Tropomyosin 2
5 Actin1
6 Calreticulin 
7 Actin-binding/filamin-like protein 
8 Actin-binding/filamin-like protein 
9 Paramyosin
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